Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11154MR)

This product GTTS-WQ11154MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1 gene. The antibody can be applied in Diffuse scleroderma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454
UniProt ID P17181
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11154MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7481MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GC-1008
GTTS-WQ9406MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ10099MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ407MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ10782MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ1405MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ5140MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ1784MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW